Related Experiment Video
Updated: Jul 31, 2025
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV
Marylee W Tailor1, Elias B Chahine2, David Koren3
1Nova Southeastern University, Fort Lauderdale, FL, USA.
Objective:
To review the efficacy, safety, and role of lenacapavir (LEN) in the treatment of HIV-1 infection.
Data Sources:
A literature search was performed using PubMed and Google Scholar (through March 2023) with the search term LEN and GS-6207. Other resources included abstracts presented at recent conferences, the manufacturer's Web site, and prescribing information.
Study Selection And Data Extraction:
All relevant articles, trial updates, and conference abstracts in the English language were included.
Data Synthesis:
Lenacapavir represents a new class of antiretrovirals (ARVs) with a novel mechanism of action as a capsid inhibitor and a unique twice-a-year subcutaneous administration schedule. Lenacapavir when combined with other ARVs has proven to benefit heavily treatment-experienced (HTE) patients with HIV-1 infection in achieving viral suppression and immune restoration.
Relevance To Patient Care And Clinical Practice In Comparison With Existing Drugs:
Lenacapavir is a new treatment option that patients who are HTE can consider adding as part of an ARV regimen.
Conclusions:
Lenacapavir is an effective and well-tolerated option for HTE patients which is a valuable addition to the arsenal of ARVs.
Related Concept Videos
01:10Retrovirus Life Cycles
02:33Retroviruses
01:26Size and Structure of Viral Genomes